GlobalData on MSN12d
EC approves AstraZeneca’s Fasenra for EGPA treatment
Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...
GlobalData on MSN1mon
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with ...
biopharma-reporter12d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
The Pharma Letter13d
EU approval for Fasenra in eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients ...
Medscape12d
Fasenra Approved in Europe for Rare Blood Vessel Disorder
The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...
Nasdaq13d
AstraZeneca’s Fasenra approved in EU for EGPA
AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
Stockhouse1mon
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s FASENRA ...
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up ...
Pharmabiz12d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
AstraZeneca’s Fasenra approved in EU for EGPA
Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or ...
Yahoo Finance12d
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a ...
PharmiWeb13d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...